Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• "Moderate Buy" consensus from 26 analysts (16 buys, 8 holds, 2 strong buys) with an average 12‑month price target of $826.59 and notable broker targets ranging from about $762 (RBC) to $995 (Guggenheim).
• Q1 results topped estimates — revenue $3.61B (up ~19%) and EPS $9.47 vs $8.91 — and the company announced a $3 billion share buyback, though net income fell ~10% YOY and the stock dipped on the news.
• Insiders sold 3,774 shares (~$2.94M) over the past three months while institutions own ~83.3% of the stock; Regeneron also pays a quarterly dividend of $0.94 ($3.76 annual, ~0.5% yield).

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twenty-six analysts that are currently covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $826.5909.

Several equities research analysts recently weighed in on REGN shares. Bank of America raised Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and upped their price target for the stock from $627.00 to $860.00 in a research note on Wednesday, January 7th. Zacks Research cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 6th. Royal Bank Of Canada reduced their price target on Regeneron Pharmaceuticals from $779.00 to $762.00 and set a "sector perform" rating on the stock in a research note on Thursday. Evercore upped their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a research note on Thursday, January 22nd. Finally, Sanford C. Bernstein reduced their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 8th.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a "sector perform" stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today's weaker price action. Regeneron drops despite Q1 beat

Insider Transactions at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares of the company's stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 3,774 shares of company stock valued at $2,942,738. Insiders own 7.02% of the company's stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. WPG Advisers LLC grew its stake in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 25 shares during the last quarter. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $29,000. Board of the Pension Protection Fund purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $701.42 on Friday. The stock has a market cap of $74.15 billion, a price-to-earnings ratio of 17.09, a PEG ratio of 1.61 and a beta of 0.30. The business's fifty day moving average is $756.81 and its 200 day moving average is $736.41. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $821.11. The company has a quick ratio of 3.39, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to analysts' expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm's revenue for the quarter was up 19.0% on a year-over-year basis. During the same period in the prior year, the firm earned $8.22 earnings per share. Research analysts expect that Regeneron Pharmaceuticals will post 36.05 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.